Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.

WHO 2013 guidelines recommend universal treatment for HIV-infected children younger than 5 years. No paediatric trials have compared nucleoside reverse-transcriptase inhibitors (NRTIs) in first-line antiretroviral therapy (ART) in Africa, where most HIV-infected children live. We aimed to compare st...

Full description

Bibliographic Details
Main Authors:	Mulenga, V, Musiime, V, Kekitiinwa, A, Cook, A, Abongomera, G, Kenny, J, Chabala, C, Mirembe, G, Asiimwe, A, Owen-Powell, E, Burger, D, McIlleron, H, Klein, N, Chintu, C, Thomason, M, Kityo, C, Walker, A, Gibb, D
Format:	Journal article
Language:	English
Published:	Elsevier 2016

Similar Items

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
by: Green, H, et al.
Published: (2007)

Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
by: Musiime, V, et al.
Published: (2014)

Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
by: L'homme, R, et al.
Published: (2008)

Improved adherence to antiretroviral therapy observed among HIV-infected children whose caregivers had positive beliefs in medicine in Sub-Saharan Africa
by: Abongomera, G, et al.
Published: (2016)

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
by: Gibb, D, et al.
Published: (2002)

Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
by: Ndembi, N, et al.
Published: (2010)

Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
by: Burger, D, et al.
Published: (2010)

Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
by: Lanier, E, et al.
Published: (2004)

Stability-indicating methods for quantitative determination of zidovudine and stavudine in capsules
by: Maria Inês R. M. Santoro, et al.
Published: (2006-04-01)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
by: Munderi, P, et al.
Published: (2010)

Determining targets for antiretroviral drug concentrations: a causal framework illustrated with pediatric efavirenz data from the CHAPAS-3 trial
by: Schomaker, M, et al.
Published: (2024)

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
by: Musiime, V, et al.
Published: (2010)

The effect of diurnal variation, CYP2B6 genotype, and age on the pharmacokinetics of nevirapine in African Children
by: Bienczak, A, et al.
Published: (2016)

Equilibrium solubility versus intrinsic dissolution: characterization of lamivudine, stavudine and zidovudine for BCS classification
by: André Bersani Dezani, et al.
Published: (2013-12-01)

The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.
by: Lachlan R Gray, et al.
Published: (2013-01-01)

Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
by: Oudijk, J, et al.
Published: (2012)

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
by: Bienczak, A, et al.
Published: (2016)

Plasma efavirenz exposure, sex, and age predict virological response in HIV-infected African children.
by: Bienczak, A, et al.
Published: (2016)

Simultaneous Determination of Lamivudine, Zidovudine and Abacavir in Tablet Dosage Forms by RP HPLC Method
by: D. Anantha Kumar, et al.
Published: (2010-01-01)

Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
by: Gupta, R, et al.
Published: (2010)

Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets
by: Bienczak, A, et al.
Published: (2017)

Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
by: Wolbers, M, et al.
Published: (2007)

High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.
by: Kim Steegen, et al.
Published: (2014-01-01)

Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study
by: Levitt Naomi S, et al.
Published: (2010-07-01)

Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
by: Kavindhran Velen, et al.
Published: (2013-01-01)

Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children
by: Kekitiinwa, A, et al.
Published: (2016)

Abacavir versus Zidovudine-based regimens for treatment of HIV-infected children in resource limited settings: a retrospective cohort study
by: Teshale Ayele Mega, et al.
Published: (2020-03-01)

Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
by: Mulenga, V, et al.
Published: (2010)

Once- versus twice-daily abacavir and lamivudine in African children: the randomised controlled ARROW Trial
by: Musiime, V, et al.
Published: (2016)

Development of Severe Anemia and Changes in Hemoglobin in a Cohort of HIV-Infected Ugandan Adults Receiving Zidovudine-, Stavudine-, and Tenofovir-Containing Antiretroviral Regimens
by: Rosalind Parkes-Ratanshi, et al.
Published: (2015-09-01)

Development and validation of RP-HPLC method for simultaneous determination of lamivudine, stavudine, and zidovudine in perfusate samples: Application to the Single-Pass Intestinal Perfusion (SPIP) studies
by: Thaisa Marinho Dezani, et al.
Published: (2021-10-01)

Is stavudine worth saving?
by: Tom Boyles
Published: (2012-06-01)

Human adenovirus DNA polymerase is evolutionarily and functionally associated with human telomerase reverse transcriptase based on in silico molecular characterization that implicate abacavir and zidovudine
by: Toluwase Hezekiah Fatoki
Published: (2023-06-01)

Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects
by: Haberer, J, et al.
Published: (2011)

Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
by: Fillekes, Q, et al.
Published: (2013)

Post-dispensing stability surveillance: Stavudine
by: Kamsaladevi K. Naidoo, et al.
Published: (2009-06-01)

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.
by: Ssali, F, et al.
Published: (2006)

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
by: McClernon Daniel, et al.
Published: (2009-04-01)

Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.
by: Fillekes, Q, et al.
Published: (2012)

Getting drug doses right in children with tuberculosis (TB)
by: H. McIlleron
Published: (2014-04-01)